Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | MDM2 positive |
Gene Variant Detail | |
Relevant Treatment Approaches |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
MDM2 positive | triple-receptor negative breast cancer | sensitive | YF438 | Preclinical | Actionable | In a preclinical study, YF438 treatment inhibited H3 and H4 acetylation, promoted Mdm2 degradation, led to growth inhibition and increased apoptosis in triple-negative breast cancer cell lines in culture, and reduced tumor growth and metastasis, extended overall survival in an orthotopic autograft model (PMID: 33985974). | 33985974 | |
MDM2 positive | triple-receptor negative breast cancer | sensitive | Doxorubicin + YF438 | Preclinical | Actionable | In a preclinical study, YF438 and Adriamycin (doxorubicin) combination treatment synergistically inhibited tumor growth compared to either drug alone in an orthotopic autograft model of triple-negative breast cancer (PMID: 33985974). | 33985974 |